RNA Formulation Videos
-
Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage
2/10/2025
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
-
Next-Generation RNA Modality Supply Considerations
Together, Life Edit Therapeutics’ April Sena and Sanofi’s Troiano share their perspectives on raw material quality & IP-related considerations for managing the supply chain for next-generation RNA modalities.
-
Transforming Nanoparticles By Continuous Manufacturing
9/13/2025
Discover how continuous manufacturing of nanoparticles can improve process efficiency, reduce costs, and increase the quality of the final drug product.
-
How To Successfully Control The Upscaling Of Your LNP Formulation
5/28/2025
Discover key strategies for controlling LNP formulation and upscaling. Explore the science behind lipid nanoparticles, critical parameters, and achieving effective turbulent mixing for optimal outcomes.
-
How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing
5/23/2024
Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.
-
How To Bring (Any) mRNA To Life: Simplifying Nucleic Acid Encapsulation
5/6/2024
New technologies for the encapsulation of nucleic acids, such as FDmiX, can potentially overcome limitations of currently available standard mixing technologies.
-
R&D & CMC Priorities For LNPs Beyond Cell-Specific Delivery
12/4/2024
It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches.
-
Scale Up And Manufacturing Of RNA-LNPs For A COVID-19 Vaccine
4/13/2022
Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.
-
Software For Liquid Nanoparticle (LNP) Systems
12/6/2024
Optimize your LNP research with KNAUER's innovative software. Streamline your workflow, overcome challenges, and achieve optimal results with ease.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?